Commercial Leqembi sales grow again after subcutaneous approvals PharmaphorumBiogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.NeuroscienceRead full story pharminent July 29, 2026 (Last updated: July 30, 2026) Pharmaphorum Biogen/Eisai’s Alzheimer’s drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations. Neuroscience Read full story Post navigation Previous: Eisai and CORE Biomedicine agree on global licence for oncology pipelineNext: Vertex, AbCellera Partner on Next-Generation T-Cell Engagers for Autoimmune Disease Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026